Alzamend Neuro Inc 's ROA from the first quarter of 2026 to the first quarter of 2026 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Alzamend Neuro Inc 's ROA in the first quarter of 2026?
Alzamend Neuro Inc recorded a cumulative net loss of $-9 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -98.76%.

However, within the Healthcare sector 928 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the fourth quarter of 2026 from 4528 to 5089.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jul 31 2026) I. Quarter	(Apr 30 2026) IV. Quarter	(Jan 31 2026) III. Quarter	(Oct 31 2025) II. Quarter	(Jul 31 2025) I. Quarter
Y / Y Total Assets Change	35.01 %	304.2 %	628.75 %	1.68 %	278.88 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-9	-9	-8	-6	-7
Return On Assets (TTM)	-98.76 %	-101.34 %	-148.02 %	-155.47 %	-164.97 %
ALZN's Total Ranking	# 5089	# 4528	# 4620	# 4707	# 5490
Total Assets (TTM) in million	9	19	5	5	6
Seq. Total Assets Change	-54.09 %	304.2 %	-9.6 %	-19.52 %	37.45 %
Seq. Net Income Change	-	-	-	-	-

ALZN's 5 Years Annual ROA >> Back to ALZN Management Effectiveness >> Compare ALZN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 437
Sector	# 929
Overall	# 5103

Return On Assets Statistics
High	Average	Low
-103.78 %	-193.63 %	-391.69 %
(Apr 30 2022)		(Apr 30 2024)

Financial Statements
Alzamend Neuro Inc 's Assets	$ 9 million	ALZN's Balance sheet
Alzamend Neuro Inc 's Income	$ -3 million	Quarterly ALZN's Income Statement
ALZN's Income by Division		See ALZN's Income by Division

Annual Return On Assets	(Apr 30 2026) FY 2026	(Apr 30 2025) FY 2025	(Apr 30 2024) FY 2024	(Apr 30 2023) FY 2023	(Apr 30 2022) FY 2022
Y / Y Total Assets Change	304.2 %	628.75 %	-89.32 %	-59.25 %	130.53 %
Total Assets in million	19	5	1	6	15
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	9	-5	-10	-15	-12
Annual Return On Assets	47.3 %	-110.91 %	-1574.93 %	-251.51 %	-85.16 %

ALZN's 5 Years Annual ROA >> Back to ALZN Management Effectiveness >> Compare ALZN ROA to its Competitors

Comment on ALZN's ROA in the fiscal year ending 2026

In the fiscal year 2026 ROA improved to 47.3 % compared to prior year, due to annual net income growth of % to $8.80 million, while value of Alzamend Neuro Inc 's overall assets grew just by 304.2 % to $18.61 million, compared to $18.61 a year before.

More Return On Assets Ratios
ALZN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ALZN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ALZN's Competitors
Subscribers only: Roa for Alzamend Neuro Inc 's Suppliers
Subscribers only: Return On Assets for ALZN's Customers

You may also want to know
ALZN's Roi	ALZN's Inventory Turnover Ratio	ALZN's Growth Rates	ALZN's Dividend Comparisons
	ALZN's Profitability Ratios	ALZN's Asset Turnover Ratio	ALZN's Dividend Growth
ALZN's Roe	ALZN's Valuation Ratios	ALZN's Financial Strength Ratios	ALZN's Dividend Payout Ratio

Companies with similar Return On Assets at Jul 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-18T15:21:03+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.